Clinical Trials Logo

Myopia clinical trials

View clinical trials related to Myopia.

Filter by:

NCT ID: NCT04980456 Completed - Myopia Clinical Trials

Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses

Start date: August 5, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the clinical performance of TOTAL30 contact lenses with Biofinity contact lenses over 30 days of daily wear.

NCT ID: NCT04976244 Recruiting - Pathologic Myopia Clinical Trials

Brolucizumab for CNV Associated With Pathologic Myopia

COASTUAbaCNV
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.

NCT ID: NCT04967287 Active, not recruiting - Myopia Clinical Trials

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation

MyopiaX-1
Start date: November 16, 2021
Phase: N/A
Study type: Interventional

The purpose of this trial is to investigate the safety and efficacy of MyopiaX - a digital treatment intended to slow the progression of myopia in children and adolescents.

NCT ID: NCT04952181 Not yet recruiting - Clinical trials for Calculation of Intraocular Lens in High Myopic Cataractous Patients

Comparison Between Different Investigations Used in Intraocular Lens Calculation in High Myopic Cataractous Patients

Start date: July 2021
Phase: N/A
Study type: Interventional

the purpose of the study is to compare the accuracy of optical and ultrasonic biometry in intraocular lens (IOL) calculation in high myopic cataractous patients

NCT ID: NCT04947735 Active, not recruiting - Myopia Clinical Trials

CYPRESS Efficacy and Safety Study Extension

CYPRESS
Start date: July 19, 2021
Phase: N/A
Study type: Interventional

This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.

NCT ID: NCT04942925 Completed - Myopia Clinical Trials

Clinical Comparison of Two Daily Disposable Contact Lenses - Pilot Study 3

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the overall performance of PRECISION1™ contact lenses when compared to INFUSE™ contact lenses.

NCT ID: NCT04928144 Completed - Myopia Clinical Trials

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

Start date: July 2, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, first-in-human dose-escalation study of SHJ002 Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional children will receive the highest tolerated concentration for 28 days.

NCT ID: NCT04927117 Recruiting - Cataract Clinical Trials

Evaluation of Visual Acuity in Myopic Cataract Patients Using Trifocal Intraocular Lens

Start date: July 1, 2020
Phase:
Study type: Observational

The PanOptix trifocal IOL is a new trifocal intraocular lens which is proved to provide good range of vision for distance, intermediate and near and good visual quality in cataract patients with normal axial length. But whether it can get the same visual quality in myopia is still unknown

NCT ID: NCT04923841 Recruiting - Myopia Clinical Trials

Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine

Start date: September 9, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the effect of bright light therapy, myopic defocus, atropine and the combination in myopia control in schoolchildren.

NCT ID: NCT04922151 Recruiting - Clinical trials for Pathological Myopic Choroidal Neovascularization

601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV